Grand Rounds| Dr. Charles B. Nemeroff | “The Status of Laboratory Testing to Predict Antidepressant Response: Problems and Promises”
2026-01-23 12:00 - 13:15 (America/Chicago)
Hybrid Event – WisPIC 6001 Research Park Blvd, Madison WI 53719, Commons Room 1616 or Virtual
Light refreshments will be provided from 12:00-12:15pm and the presentation will run from 12:15-1:15pm.

About the Speaker:

Charles B. Nemeroff, MD, PhD is Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the Dell Medical School, University of Texas at Austin. He also directs the Institute for Early Life Adversity Research within the department as part of the Mulva Clinic for the Neurosciences, and co-directs the Center for Psychedelic Research and Therapy. Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He received his medical degree and doctorate degrees in neurobiology from the University of North Carolina (UNC) School of Medicine.
Dr. Nemeroff has received a number of research and education awards including the Mrazek Award in Psychiatric Pharmacogenomics, Kempf Award in Psychobiology, the Samuel Hibbs Award, Research Mentoring Award, Judson Marmor Award and the Vestermark Award from the American Psychiatric Association (APA), the Mood Disorders Award, Bowis Award and Dean Award from the ACP and the Julius Axelrod Award for mentoring from the ACNP. He was elected to the National Academy of Medicine in 2002. He was also named Alumnus of the Year from the University of North Carolina and from the UNC Medical School. He received the Doctorate Honoris Causa from Maimonides University in Buenos Aires in 2015 and a Professor Honoris Causa from Favaloro University in Buenos Aires in 2021.
Dr. Nemeroff is a member of the APA Council on Research and Chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments. His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,200 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.
Dr. Nemeroff has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, MD) of the Textbook of Psychopharmacology, published by the APA Press and now in its Fifth Edition; and is the co-editor in chief of a new journal published by Elsevier, Personalized Medicine in Psychiatry. He is the past President of the Anxiety and Depression Association of America (ADAA).

Related Articles:
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder

Grand Rounds | Dr. Larissa Albantakis
2026-03-13 12:00 - 13:15
Hybrid Event – WisPIC 6001 Research Park Blvd, Madison WI 53719, Commons Room 1616 or Virtual
Light refreshments will be provided from 12:00-12:15pm and the presentation will run from 12:15-1:15pm.

About the Speaker:

Larissa Albantakis, PhD is a computational neuroscientist and Assistant Professor of Computational Psychiatry. Her research explores the relationship between causation, complexity, consciousness, and cognition, and their quantitative assessments in neural network models and neurophysiological data from healthy subjects and clinical patient populations. Dr. Albantakis’ research group is aimed at developing novel computational tools to analyze and model the origins, symptoms, and potential for interventions of mental disorders in a causal, mechanistic manner at the individual and group level. She is affiliated with the Center for Sleep and Consciousness at the University of Wisconsin-Madison.
Dr. Albantakis obtained her Diploma (MSc) in Physics from Ludwig-Maximilians University in Munich in 2007, and her PhD in Computational Neuroscience from Universitat Pompeu Fabra in Barcelona in 2011 under the supervision of Dr. Gustavo Deco. Her PhD research focused on using large-scale, biophysically-realistic neural models and dynamical systems theory to understand the neural mechanisms underlying sensorimotor decision-making in contexts where subjects have multiple choice-alternatives and the option to “change one’s mind.”
Dr. Albantakis has been at the University of Wisconsin-Madison since 2012, where she worked together with Dr. Giulio Tononi before starting her own research group in 2022. Her work with Dr. Tononi proved essential for developing (1) the mathematical formalism of the integrated information theory (IIT) of consciousness; (2) a demonstration of the adaptive advantages of recurrent architectures and high information integration in evolving artificial organisms; (3) a body of work assessing causal relations across micro and macro spatio-temporal scales in artificial neural networks; (4) an account of the relation between causal and dynamical complexity in discrete dynamical systems; (5) a quantitative framework of actual causation (“what caused what”); and (6) a formal account of informational autonomy of an agent from its environment.
Learning objectives:
1) Describe the core biophysical principles of transcranial electrical stimulation with temporal interference (TES-TI)—including carrier vs. envelope frequencies, steerability, and the depth/focality tradeoffs relative to conventional tES and other neuromodulation modalities.
2) Identify key safety, tolerability, and feasibility considerations for TES-TI in humans (e.g., frequency-dependent tolerability, acute adverse events, and current intensity constraints), and interpret how these considerations inform trial design and monitoring in psychiatric populations.
3) Identify the interdisciplinary considerations that would need alignment before TES-TI could be responsibly tested in psychiatric populations (e.g., patient selection, endpoints meaningful to care teams, risk communication, and follow-up burden).

Related Articles:
Albantakis L and Tononi G (in press) Precision Neuromodulation in Psychiatry: Focus on Temporal Interference Stimulation. American Journal of Psychiatry.
Missey F, Acerbo E, Dickey AS, et al.: Non-invasive Temporal Interference Stimulation of the Hippocampus Suppresses Epileptic Biomarkers in Patients with Epilepsy: Biophysical Differences between Kilohertz and Amplitude Modulated Stimulation. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation 2025; 0

Grand Rounds | Dr. Chardée A. Galán
2026-05-08 12:00 - 13:15

Grand Rounds | Speaker TBD
2026-07-10 12:00 - 13:15, 2026-09-11 12:00 - 13:15, 2026-11-20 12:00 - 13:15, 2027-01-15 12:00 - 13:15, 2027-03-12 12:00 - 13:15

Greenfield Lecture | Dr. Melissa Brotman
2026-10-23 12:00 - 13:15

Grand Rounds | Dr. Constance Guille
2027-04-09 12:00 - 13:15

Grand Rounds | Dr. Alan Schatzberg
2027-05-21 12:00 - 13:15
